Alexion Pharmaceuticals, Inc. (ALXN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN)

ALXN 182.50

0.0%

Jul 28 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rkrw who wrote (383)	11/10/2003 6:47:17 PM
From: Miljenko Zuanic	Read Replies (1) of 824

<<I'd guess the probably not-so-prospectively defined secondary endpoints >> Do you need to be critical all the time? Target was 30% reduction in in death/MI, and nowhere in PR is noted. Also, I was hoping for ~50% reduction in mortality, or at least 2% points (absolute). Data are worse than I was speculating early. Message 19200155 Message 19196679 and <<IF you take Bell’s comment on CONSISTENCY as granted, than my take is that there was not significant benefit in all-cause mortality while Pexe did reduce non-fatal MI. Which would explain valve group contribution to overall result. However, this will reduce their marketing advantage, as mortality is great factor than MI.>> Message 19193345 Jan, you are mixing tomato and orange. Miljenko PS: ALXN management is join Zudija club

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next